Repetitive transcranial magnetic stimulation for depression after colorectal cancer treatment with chemotherapy‐induced peripheral neuropathy: A case report Authors: Kosei Esaki, Takeo Saito, Yuki Matsuda, Yueren Zhao, Hiroyuki Kimura, Masashi Ikeda, Tsuyoshi Kitajima, Nakao Iwata Published: 2026 ABSTRACT AbstractBackgroundTreatment of depression in patients with cancer requires individualized decision‐making considering physical symptoms, drug interactions, adverse effects, treatment burden, and acceptability. We report a patient with persistent depression after colorectal cancer treatment, in whom pharmacotherapy was constrained by insufficient efficacy and tolerability, improvement with modified electroconvulsive therapy (mECT) was temporary, and reintroduction of mECT was difficult. She subsequently received repetitive transcranial magnetic stimulation (rTMS).Case PresentationA woman in her 60s developed depression after emergency surgery for lower gastrointestinal perforation caused by descending colon cancer and later developed chemotherapy‐induced peripheral neuropathy (CIPN) after postoperative chemotherapy. Pharmacotherapy produced insufficient improvement. Although 10 mECT sessions led to improvement, symptoms recurred after discharge. Reintroduction of mECT was not possible because of strong fear of the treatment and general anesthesia. She was referred to our hospital and received 27 rTMS sessions without changes in psychotropic medication. Her 17‐item Hamilton Depression Rating Scale and Clinical Global Impressions–Severity (CGI‐S) scores improved from 19 to 8 and from 4 to 1, respectively, whereas the pain Numerical Rating Scale score remained 8. Behavior and daily functioning also improved. Six months after treatment, limb discomfort persisted, but she could still perform household chores and go out. The referring physician rated the CGI‐S score as 1.ConclusionWhen pharmacotherapy for depression after cancer treatment is constrained by insufficient efficacy or tolerability, and the benefit of mECT is transient or its reintroduction is difficult, rTMS may be considered as a treatment option.Keywords: chemotherapy‐induced peripheral neuropathy, colorectal cancer, depression, electroconvulsive therapy, repetitive transcranial magnetic stimulation BACKGROUND Among patients with cancer in non‐palliative care settings, the pooled prevalence of depression ranges from 8% to 24%, depending on the assessment method, cancer type, and treatment timing. 1 Depressive symptoms are more frequent among colorectal cancer survivors than in the general population (19.0% vs. 12.8%) and are associated with poorer quality of life. 2 Additionally, major depression in patients with cancer has been associated with shorter survival. 3 Treatment of depression in patients with cancer should be individualized, considering physical symptoms, adverse effects of antidepressants, and interactions with concomitant medications, including anticancer agents. 4 A study using a Japanese employer‐based health insurance claims database found that antidepressants were less likely to be prescribed among patients diagnosed with major depressive disorder following cancer diagnosis than among matched patients without cancer, suggesting possible undertreatment. 5 Antidepressants are an important option, but evidence regarding their efficacy and tolerability in patients with cancer remains limited. 6 Electroconvulsive therapy (ECT), while effective for severe depression, requires general anesthesia, and periprocedural management. 7 Conversely, repetitive transcranial magnetic stimulation (rTMS) is noninvasive, does not require general anesthesia, and has demonstrated efficacy and tolerability in major depressive disorder. 8 , 9 However, reports of rTMS in patients with cancer remain limited. 10 , 11 Herein, we describe the clinical course of a patient with persistent depression and chemotherapy‐induced peripheral neuropathy (CIPN) after colorectal cancer treatment, in whom pharmacotherapy and modified ECT (mECT) were constrained and who subsequently received rTMS. CASE PRESENTATION Four years prior, a woman in her 60s underwent emergency surgery for lower gastrointestinal perforation caused by stage IVC descending colon cancer with peritoneal dissemination. Around that time, depressed mood, insomnia, agitation, and suicidal ideation emerged and worsened, leading to the diagnosis of depression. The patient also underwent postoperative chemotherapy with capecitabine and oxaliplatin. Subsequently, she developed worsening pain in both fingers and numbness in the distal portions of all four limbs and was diagnosed with CIPN. Amitriptyline (5 mg/day) was discontinued after 2 weeks because of akathisia, before an adequate dose and duration could be achieved. Vortioxetine (20 mg/day), initiated during a 3‐week psychiatric hospitalization, was continued for 10 weeks but did not yield sustained improvement. Sertraline (6.25 mg/day) was also discontinued after 1 week because of akathisia. Other medications, including valproate, gabapentin, clonazepam, tramadol, and alprazolam, were used but did not sufficiently improve depression, agitation, and pain. Owing to persistent agitation and inadequate pain control, she was rehospitalized and mECT was initiated. After the first session, she developed a strangulated ileus requiring emergency gastrointestinal surgery, and mECT was temporarily interrupted. Causality between mECT and the ileus could not be established. Approximately 2 months later, after her physical condition had stabilized, mECT was resumed, reaching a total of 10 sessions. After completion of mECT, most depressive symptoms improved, although diminished interest and insomnia persisted. However, relapse began soon after discharge, and by 1 month after discharge, most depressive symptoms, including depressed mood, insomnia, decreased appetite, and fatigue or loss of energy, had largely recurred. Another course was proposed; however, she declined because of strong fear of mECT and general anesthesia. Given that pharmacotherapy had not provided sufficient improvement and that the benefit of mECT was not sustained, with reintroduction being difficult, rTMS was proposed. After providing consent, she was referred to our hospital and admitted for a planned course of 30 rTMS sessions administered five times per week. At the time of referral to our hospital, she had no suicidal ideation but exhibited depressed mood, diminished interest or pleasure, insomnia, decreased appetite, fatigue or loss of energy, feelings of worthlessness, and impaired concentration. These symptoms met the DSM‐5 diagnostic criteria for major depressive disorder. She also reported severe pain and numbness in her hands and feet and spent most of her time in her room rather than interacting with other patients. At admission, her scores for the 17‐item Hamilton Depression Rating Scale (HAM‐D), Clinical Global Impressions–Severity (CGI‐S), and Numerical Rating Scale (NRS) were 19, 4, and 8, respectively. Her medications, including quetiapine (100 mg/day), mirtazapine (15 mg/day), lemborexant (5 mg/day), suvorexant (20 mg/day), and alprazolam (1.2 mg/day), were continued after admission. Anticancer treatment had been completed by the time rTMS was initiated. During the acute rTMS course, no psychotropic medication was added, discontinued, or dose‐adjusted. Using the NeuroStar TMS System, high‐frequency rTMS was delivered over the left dorsolateral prefrontal cortex at 120% of the resting motor threshold. The protocol included 10‐Hz stimulation, 4‐s trains, 26‐s intertrain intervals, 3000 pulses per session, 37.5 min per session, and five sessions per week. The stimulation site, intensity, frequency, and number of pulses per session were consistent with the device‐specific criteria for the NeuroStar TMS System specified in the Japanese Society of Psychiatry and Neurology guidelines for the appropriate use of rTMS. 12 After 15 sessions, the HAM‐D, CGI‐S, and NRS scores were 13, 2, and 7, respectively. She began spending more time outside her room, interacting with other patients, and participating in occupational therapy. However, given the psychological burden of hospitalization, she strongly wished to be discharged early. Therefore, rTMS was discontinued after 27 sessions. At the end of treatment, the HAM‐D score had improved to 8 and the CGI‐S score to 1, whereas the NRS score returned to 8. Although her subjective pain and numbness persisted, she played table tennis during occupational therapy, smiled, and spontaneously interacted with other patients. Her family also reported improved daily activity, including a longer walking distance and an increased ability to go out. Six months after treatment, the referring physician obtained follow‐up information from the patient and her family. Although limb discomfort persisted, she could still perform all household chores, walk to shops, and take longer trips when driven by her husband. The CGI‐S score, rated by the referring physician, was 1. Quetiapine had been reduced to 50 mg/day, and alprazolam had been replaced with clonazepam (1.0 mg/day). Nonetheless, there was no substantial treatment intensification, such as the addition or dose increase of an antidepressant. DISCUSSION In this case, pharmacotherapy was constrained by insufficient efficacy and tolerability, and improvement with mECT was temporary. Following rTMS, the HAM‐D score improved from 19 to 8 and the CGI‐S score from 4 to 1. Although the NRS score remained unchanged, behavior and daily functioning improved. At 6 months, the referring physician rated the CGI‐S score as 1, and the functional improvement was maintained. Although administered at an adequate dose and duration, vortioxetine did not produce sustained improvement. Meanwhile, amitriptyline and sertraline were discontinued because akathisia occurred even at low doses. Thus, both the efficacy and tolerability of pharmacotherapy were constrained. Following the first mECT session, a strangulated ileus developed, requiring emergency surgery and interruption of treatment. Although causality could not be established, this physical event contributed to the patient's fear of mECT and general anesthesia. In total, the patient received 10 mECT sessions, which yielded temporary improvement; symptoms subsequently recurred, and she declined reintroduction of mECT. Thus, rTMS, which does not require general anesthesia, had a clear clinical rationale. In patients with depression in whom pharmacotherapy has been insufficient and who are reluctant to undergo ECT or general anesthesia, rTMS may be a feasible treatment option when an urgent therapeutic response is not required. This case does not suggest that rTMS is superior to ECT; rather, it illustrates that rTMS may provide a more acceptable treatment option when ECT is difficult to initiate or reintroduce. Treatment acceptability and the feasibility of completing treatment are also important. Dropout rates for antidepressants, ECT, and rTMS cannot be directly compared because the study populations, treatment durations, and definitions of dropout differ. In major depressive disorder, dropout rates with rTMS are comparable to those with sham stimulation, 13 and all‐cause dropout did not significantly differ between ECT and high‐frequency rTMS. 14 In the present case, mECT was not reintroduced because the patient declined it, whereas rTMS ended after 27 sessions because she strongly requested early discharge owing to the psychological burden of hospitalization. Neither event represented typical dropout caused by a treatment‐related adverse effect. Reports of rTMS in patients with cancer remain scarce. In a scoping review of 17 studies including 406 participants, most studies were small, and the stimulation sites, stimulation parameters, number of treatment sessions, target symptoms, assessment scales, and assessment time points varied substantially across studies. 11 Thus, the efficacy of rTMS for depression in patients with cancer remains uncertain. In this patient, depressive symptoms and functioning improved despite persistent limb pain and discomfort. Therefore, this improvement cannot be attributed to alleviation of CIPN or a direct analgesic effect of rTMS. Nevertheless, the recovery of daily functioning despite persistent physical symptoms, and its maintenance at 6 months, are clinically meaningful. This report has several limitations: its single‐case design without a control condition; the inability to exclude the effects of the natural course, inpatient environment, occupational therapy, and supportive care; and the absence of a repeat HAM‐D assessment at 6 months. Moreover, medications were adjusted after treatment; hence, the 6‐month outcome cannot be attributed to rTMS alone. Conversely, psychotropic medications remained unchanged during the acute rTMS course; thus, improvement at treatment completion cannot be explained solely by medication adjustment. This case does not establish the efficacy of rTMS in patients with cancer; rather, it documents improvement in depressive symptoms and daily functioning following rTMS in a patient with persistent depression and CIPN after colorectal cancer treatment, in whom pharmacotherapy and mECT were constrained. CONCLUSION We administered rTMS for depression after colorectal cancer treatment in a patient with coexisting CIPN, in whom pharmacotherapy was constrained by insufficient efficacy and tolerability, improvement with mECT was temporary, and reintroduction of mECT was difficult. Depressive symptoms and daily functioning improved despite persistent pain and limb discomfort. At 6 months, the CGI‐S score rated by the referring physician was 1, and improvement in daily functioning was maintained. In similar cases, rTMS may be considered as a treatment option. AUTHOR CONTRIBUTIONS Kosei Esaki conceived the report, collected and interpreted the clinical data, and drafted the manuscript. Takeo Saito, Yuki Matsuda, Yueren Zhao, Hiroyuki Kimura, Masashi Ikeda, Tsuyoshi Kitajima, and Nakao Iwata contributed to the interpretation of the clinical findings and critically reviewed and revised the manuscript. All authors approved the final version of the manuscript and agreed to be accountable for all aspects of the work. CONFLICT OF INTEREST STATEMENT Takeo Saito is a Field Editor and Editorial Board member of Psychiatry and Clinical Neurosciences Reports and a co‐author of this article. To minimize bias, he was excluded from all editorial decision‐making related to the acceptance of this article for publication. The remaining authors declare no conflicts of interest. ETHICS APPROVAL STATEMENT Ethics committee approval was not required for this single‐case report in accordance with institutional policy. PATIENT CONSENT STATEMENT Written informed consent was obtained from the patient for the publication of this case report. CLINICAL TRIAL REGISTRATION N/A. ACKNOWLEDGMENTS The authors are grateful to the patient and her family for their cooperation and for providing follow‐up information. During the preparation of this manuscript, the authors used ChatGPT (OpenAI) to assist with the English translation of text written by the authors. All AI‐assisted content was reviewed and revised by the authors, who take full responsibility for the final manuscript. No funding was received for this work. DATA AVAILABILITY STATEMENT All data supporting the findings of this case report are included in the article. Additional clinical data are not publicly available because of patient privacy and confidentiality. REFERENCES Associated Data Data Availability Statement All data supporting the findings of this case report are included in the article. Additional clinical data are not publicly available because of patient privacy and confidentiality.